Parliamentary Debates (Hansard)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Directory of Companies A
65 Directory of Companies A An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe 3B PHARMACEUTICALS GMBH Magnusstraße 11 12489 BERLIN DE 3M BELGIUM Canadastraat 11, Haven 1005 2070 ZWIJNDRECHT BE 3V-LSI Rubicondreef 18 3561 JC UTRECHT NL of Companies 4SC AG Am Klopferspitz 19a 82152 MARTINSRIED DE A & D INSTRUMENTS LTD Abingdon Science Park OX14 3YX ABINGDON GB ABBVIE DEUTSCHLAND GMBH & CO. KG Knollstrasse 67061 LUDWIGSHAFEN DE Directory ABCR GMBH Im Schlehert 10 76187 Karlsruhe, GERMANY Contact person: Dr. Ute Kiso Tel: +49 721 95061-0 - [email protected] www.abcr.de Gute Chemie. Welcome to abcr. With abcr, you have access to over 260,000 products from the organic, organometallic and inorganic specialty chemicals area. These can be conveniently ordered via our webshop www.abcr.de > Catalogue & Bulk business from grams to tons > Scale up & Commercial manufacturing from our own facility > Sourcing & Logistic management worldwide > Feasibility studies & Synthesis at the laboratory scale > Custom syntheses & Contract Manufacturing ABSORPTION SYSTEMS 440 Creamery Way Suite 300 PA 19341 EXTON US AC IMMUNE SA EPFL Innovation Park Building B 1015 LAUSANNE FR ACCELA CHEMBIO 9823 Pacific Heights Blvd # F 92121 SAN DIEGO US ACRAF S.P.A. Piazzale della Stazione 40 S. PALOMBA - POMEZIA IT ACROS ORGANICS Janssen Pharmaceuticalaan 3a 2440 GEEL BE ACS Journal of Medicinal Chemistry & ACS Medicinal Chemistry Letters Contact person: Janice E. Silverman, Acquisitions Editor Tel: +1 202-577-5975 [email protected] Journal of Medicinal Chemistry – pubs.acs.org/jmc ACS Medicinal Chemistry Letters – pubs.acs.org/acsmedchemlett In 2017 Journal of Medicinal Chemistry is celebrating 60 years of publishing the field’s best peer-reviewed research. -
Vol 34 No 3 June July 2012
D ON ON L June Vol 34 July No 3 2012 Local preservation campaigners triumph - but is the Ivy House saved? (see page 44) EST 1721 23-25 NEW END • HAMPSTEAD VILLAGE • NW3 1JD 1st Annual Cotswolds Beer Festival A taste of the countryside comes to London Thursday 21st to Sunday 24th June 2012 • Over 30 fabulous ales from the Cotswolds region • Delicious food and West Country delicacies • Live music and entertainment throughout the weekend • Meet the Brewer and other special events Don’t forget the Hampstead Summer Festival on the 24th June! See our website for up to date beer list and event information Best Tel: 020 7794 0258 London Pub of the Year 2011 twitter: @dukeofhamilton Fancy a Pint Reviewers www.thedukeofhamilton.com Awards 5 PINT RATED PUB All ales £2.70 a pint Mondays and Tuesdays. See website for ales on tap. Editorial London Drinker is published by Mike Hammersley on behalf of the London NDO Branches of CAMRA, the Campaign for Real O N Ale Limited, and edited jointly by L Sarah Bleksley and Mark Davies. Tel: 07747 494840. Material for publication should preferably be sent by e-mail to [email protected]. Correspondents unable to send letters to the editors electronically may post them to Brian Sheridan at 4, Arundel House, Heathfield Road, Croydon CR0 1EZ. Press releases should be sent by email to [email protected] Changes to pubs or beers should be reported to Capital Pubcheck, 2 Sandtoft Road, London SE7 7LR or by e-mail to [email protected]. Poor show, Lord Coe! For publication in August 2012, please send electronic documents to the editors no later than ver since the news of London’s ing rights’ at Olympic events. -
Contents Page
Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9 -
Acacia Pharma Group
This document comprises a prospectus (the “Prospectus”) relating to Acacia Pharma Group plc (the “Company” or “Acacia Pharma”) prepared in accordance with the prospectus regulation rules (the “Prospectus Regulation Rules”) of the UK Financial Conduct Authority (the “FCA”) made pursuant to section 73A of the Financial Services and Markets Act 2000, as amended (“FSMA”). This Prospectus has been approved by the FCA as the competent authority under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has been filed with and made available to the public in accordance with Rule 3.2 of the Prospectus Regulation Rules. The FCA only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company or of the quality of the Ordinary Shares that are the subject of this Prospectus. Investors should make their own assessment as to the suitability of investing in the Ordinary Shares. In addition, this Prospectus has been drawn up as a simplified prospectus in accordance with Article 14 of the Prospectus Regulation. The Belgian Financial Services and Markets Authority (“Belgian FSMA”) was notified of the passporting of this Prospectus in accordance with Article 25 of the Prospectus Regulation. The Company and the Directors, whose names appear on page 39 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Company and the Directors, the information contained in this document is in accordance with the facts and this document makes no omission likely to affect its import. -
Dśğ Admission Document Perivan Financial Print (247278) THIS ADMISSION DOCUMENT IS IMPORTANT and REQUIRES YOUR IMMEDIATE ATTENTION
dŚĞ Admission Document Perivan Financial Print (247278) THIS ADMISSION DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document, or the action you should take, you are recommended to seek your own independent financial advice from your stockbroker, bank manager, solicitor, accountant or other independent professional adviser authorised under the FSMA who specialises in advising on the acquisition of shares and other securities. This document, which is an AIM admission document and has been prepared in accordance with the AIM Rules for Companies, has been issued in connection with an application for admission to trading on AIM of the entire issued, and to be issued, share capital of the Company. This document does not constitute an offer or any part of an offer of transferrable securities to the public within the meaning of section 102B of the FSMA. Accordingly, this document does not constitute a prospectus for the purposes of section 85 of the FSMA or otherwise, and it has not been drawn up in accordance with the Prospectus Rules published by the Financial Conduct Authority and it has not been approved by or filed with the FCA or any other competent authority. The Company, whose registered office appears on page 10 and the Directors, whose names appear on page 10, accept responsibility for the information contained in this document, including individual and collective responsibility for the Company’s compliance with the AIM Rules for Companies. To the best of the knowledge and belief of the Company, the Directors (each of whom has taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information. -
A Science and Innovation Audit Report for the Midlands Engine
A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report 01 November 2016 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Contents Midlands Engine SIA – the headlines ....................................................................................1 1. Introduction to the Midlands Engine SIA...........................................................................4 2. SIA ‘hypotheses’ and ‘framework’ ...................................................................................10 3. Regional science and innovation assets and excellence..............................................19 4. Innovation strengths and our growth priorities..............................................................30 5. Market and technology drivers of change.......................................................................53 6. Innovation networks and behaviours ..............................................................................59 7. Next Steps – unlocking our productivity potential.........................................................67 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Midlands Engine SIA – the headlines 1. In Autumn 2015 the UK Government announced regional Science and Innovation Audits (SIAs) to catalyse -
A Preclinical Evaluation of the Discriminative And
NP5101_proof ■ 12 June 2013 ■ 1/11 Neuropharmacology xxx (2013) 1e11 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm 1 56 2 A preclinical evaluation of the discriminative and reinforcing 57 3 58 4 properties of lisdexamfetamine in comparison to D-amfetamine, 59 5 fi 60 6 methylphenidate and moda nil 61 7 62 a,* a a a b 8 Q5 David J. Heal , Niki W. Buckley , Jane Gosden , Nigel Slater , Charles P. France , 63 9 David Hackett c 64 10 65 a 11 RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK 66 b University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA 12 c Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke RG24 8EP, Hampshire, UK 67 13 68 14 69 15 article info abstract 70 16 71 17 Article history: Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first 72 18 Received 12 December 2012 prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic 73 19 Received in revised form hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other 74 3 April 2013 20 stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and 75 Accepted 13 May 2013 21 modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing 76 effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)- 77 22 Keywords: cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. -
BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY
Significant Capital Allowance Investment Opportunity BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease THE OPPORTUNITY Unique opportunity to acquire a new bio-science incubator facility let on a long lease to a major city council with significant capital allowances providing an attractive post tax return. Prominently located at Lower Parliament Street, Nottingham There are estimated £9,750,000 of available capital allowances to a adjacent to the existing Bio-City buildings within Nottingham’s purchaser which at a higher tax rate of 45% are worth £4,387,500 creative quarter. over a 5 year period. 150 years long-leasehold interest at a peppercorn rent from Nottingham City Council is to provide a loan to the purchaser of Nottingham City Council. £11,011,200 for a 5 years period at a fixed interest rate of 4.50% which equates to £495,484 interest per annum. No amortisation required during this period. Construction commenced in August 2015 on the new Biocity Science building over ground and 4 upper floors providing state of the art laboratory and office accommodation and extending to 52,475 sq ft Purchaser equity requirement of £6,748,800 which after interest NIA. Willmott Dixon is the appointed contractor. charges provides a net annual pre tax yield of 3.18%. To be let to Nottingham City Council for 30 years from completion of this transaction on a full repairing and insuring lease at an initial rent of Post tax annual yields are Year 1 - 7.54%, Year 2 - 6.86%, Year 3 - £714,000 per annum equating to £13.61 per sq ft. -
Nöjesliv 30 Unikt Inredda Rum
Vik här Mer om de här hotellen finns att läsa i resguiden ”London” 5 x boenden Publicerad oktober 2014 London Edition w 34 Sussex Gardens, W2 1UL Holly House Hotel Läckert inredd 1800-talsbygg- T-bana: Paddington och Edgwa- Bra alternativ om man vill läg- nad 30 meter från Oxford Street. re Road ga pengarna på annat än att Restaurangen Berners Tavern S www.pavilionhoteluk.com bara bo. Bra läge, säng och en har fått toppbetyg, nattklubb på schysst frukost. bottenvåningen. Förstklassigt. Shoreditch House Dubbelrum: Från £65. Dubbelrum: £270 (ca 2911 kr). Trendigt hotell som är en med- w 20 Hugh Street, SW1V 1RP w 10 Berners Street, W1T 3NP lemsklubb. Ganska enkla rum. T-bana: Victoria eller Sloane T-bana: Tottenham Court Road Skön stämning i loungebaren, Square. S www.edition-hotels.marriott.com/ exklusiv restaurang, takpool, fri- S www.hollyhousehotel.co.uk london sör och spa. Bland annat. Dubbelrum: Från £88. Airbnb The Pavilion w Ebor Street, Shoreditch, E1 Grym sajt som är perfekt för att Trött på tråkiga hotellrum? Prova 6AW hitta ett hemtrevligt ställe. Hyr Londons rock’n’roll-hotell med T-bana: Liverpool Street någons lägenhet eller rum, och Nöjesliv 30 unikt inredda rum. S www.shoreditchhouse.com få mycket mer för pengarna än Dubbelrum: £110. Familjerum bara en säng. (två vuxna/två barn): £135. S www.airbnb.com 5 x sajter Minilexikon Swww.visitlondon. Mysiga och ovanliga ställen som LONDON Det säger London-bon com träffar sällan fel. Bäst är funktio- Den officiella turistsajten. Här nen att hitta spännande ställen i The Tube – tunnelbanan kan du både boka hotell och närheten av där du är. -
Easter Beer Festival
F R E E Vol 35 Feb/Mar No 1 2013 CAMRA members from branches in Greater London pose before setting off to see their MPs Editorial Leeds North West and chair of the All London Drinker is published PartY ParliamentarY SaVe the Pub group on behalf of the said, “TodaY has been incrediblY poW - London Branches of CAMRA, the Campaign for Real Ale Limited, erful but please carrY on What You’re and edited jointly by doing locallY… get more people behind Tony Hedger and Mark Davies. this. You are campaigning not onlY for Tel: 07790 750024. the great British pub, You are campaign - Material for publication should preferably be ing for the nation.” AndreW Griffith, sent by e-mail to [email protected]. the MP for Burton on Trent and chair - Correspondents unable to send letters to the edi - man of the All PartY ParliamentarY Beer tors electronically may post them to n the parliamentarY debate on the Brian Sheridan at 4, Arundel House, Heathfield Ibeer dutY escalator, Charlotte Leslie, Group said, “TodaY We haVe sent a Road, Croydon CR0 1EZ. the MP for Bristol North West, said that strong message… We loVe our beer, We Press releases should be sent by email to pubs Were a ‘real World’ Version of the loVe our pubs and We’re going to fight [email protected] House of Commons, Where people de - to defend them. You can all be VerY Changes to pubs or beers should be reported to proud that todaY We haVe all plaYed our Capital Pubcheck, bate about real things. -
Economic Strategy Research Bureau
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham Trent Institutional Repository (IRep) Biotechnology, life sciences and skills in D2N2: A report for Learn Direct and the D2N2 Local Enterprise Partnership Will Rossiter, David J. Smith, Nikolas Pautz, Daniel McDonald-Junor Economic Strategy Research Bureau Nottingham Business School Nottingham Trent University July 2018 2018 Contents Executive Summary............................................................................................................................ 4 1 Introduction ................................................................................................................................ 6 1.1 Approach ................................................................................................................................. 7 2 What are life sciences and the biotech industry? ....................................................................... 9 2.1 Origins of the Biotechnology industry .................................................................................. 10 2.2 Features of the emerging UK biotechnology industry .......................................................... 13 2.3 The Bioincubator boom of the 2000-2008 ............................................................................ 14 3 Restructuring, Open Innovation and Outsourcing in the Pharmaceutical Industry ................. 17 4 The Decline in Laboratory Technician training ........................................................................ -
Title: the Rise and Rise of Biotech and Life Sciences in Nottingham Will Rossiter, David Smith, & Daniel Mcdonald-Junor
Title: The rise and rise of biotech and life sciences in Nottingham Will Rossiter, David Smith, & Daniel McDonald-Junor, Nottingham Business School Notable in this years’ Top 200 list are an increasing number of local companies involved in the applications of biotechnology and life sciences – companies like Fresenius Medical , Source Bioscience Limited, and Robinsons Healthcare. Indeed this phenomenon has come to symbolise Nottingham’s reinvention as a post-industrial economy. Recent research at Nottingham Business School has started to explain how it happened. At the start of the millennium, Nottingham looked to be a city facing serious industrial decline. Former mainstays of the local economy like Raleigh, Players, and Royal Ordnance had ceased large scale manufacturing operations in the City and employment in the sector continued to shrink as the balance of the economy shifted towards the service sector. Move forward a decade or two however, and you’ll find a different story. A new development path has been forged through the application of biotechnology and life sciences. That this should have happened in a former manufacturing city in the North Midlands is remarkable. The most obvious symbol of this is BioCity, where more than 75 bioscience-related companies have been established since 2003. Although modest in scale by the standards of bioscience concentrations in London and the South East, the emergence of bioscience in Nottingham is significant. Not least because this momentum has been sustained over a 15-year timeframe and shows no signs of slowing. Indeed BioCity is now the country’s largest life science themed business incubation facility.